tagged w/ Ovarian Cancer
-
CNN...
.
Evelyn Lauder, who created breast cancer's pink ribbon, dies at 75
By the CNN Wire Staff
updated 2:21 AM EST, Sun November 13, 2011
.
New York (CNN) -- Evelyn Lauder, a member of the Estee Lauder cosmetic company who helped create the pink ribbon symbol for breast cancer awareness, died Saturday in New York City.
She was 75.
Lauder died from complications of ovarian cancer at her home with her family by her side, the company said.
The Vienna, Austria, native fled Nazi-occupied Europe with her parents, eventually settling in New York City.
As a college freshman, she was introduced to the man she would marry, Leonard A. Lauder, the son of Estee and Joseph Lauder, who co-founded the cosmetics company.
Lauder joined the family business and rose to be senior corporate vice president and head of fragrance development worldwide.
Perhaps best known as an advocate for women's health, Lauder helped to create the pink ribbon, the now ubiquitous symbol for breast cancer awareness.
She is survived by her husband, two sons and five grandchildren.
"My mother carried the torch of our company heritage and the values that were passed to her by my grandmother, Mrs. Estee Lauder," her son, William Lauder, said in a statement.
"My mother and father were life partners as well as business partners. They nurtured the culture and growth of the Estee Lauder companies, and as we grew, my mother was our creative compass and pillar of strength. Together my family and the company celebrate the beautiful person she was."
.CNN...
.
Evelyn Lauder, who created breast cancer's pink ribbon, dies at 75... more
-
-
-
-
-
-
suzane
-
added this
-
1 year ago
- |
-
You've probably used it, or had it sprinkled on you at some time in your life. It's processed from a soft mineral compound of magnesium silicate and is called talcum powder, or just talc.
Talcum powder is manufactured by Johnson & Johnson, among others, and is widely available in drug stores. Women have been persuaded by years of advertisements to dust themselves with talcum powder to mask alleged genital odors.
While the powder has been a symbol of freshness and cleanliness for over five decades, genital talc dusting is a dangerous, but avoidable, cause of ovarian cancer, warns Dr. Samuel S. Epstein, chairman of the Cancer Prevention Coalition.
The first warning of the dangers of genital talc dusting came in a 1971 report on the identification of talc particles in ovarian cancers, a finding sharply contested by Dr. G.Y. Hildick-Smith, who was then Johnson & Johnson's medical director....You've probably used it, or had it sprinkled on you at some time in your life.... more
-
-
ajrmy
-
added this
-
2 years ago
- |
-
A new study shows that GPs often confuse the symptoms of ovarian cancer and irritable bowel syndrome. Symptoms like sharp abdominal pains and problems with eating are signs of IBS, but they're also key signs of ovarian tumours.
Among the findings --
-- Four out of five GPs wrongly thought women with early-stage ovarian cancer had no symptoms.
-- Only 27 per cent knew of NHS guidelines on what they should watch out for.
-- 69 per cent seemed unaware that women with ovarian cancer were more likely to experience sudden and persistent abdominal pain than women with IBS.
-- Most of the ovarian cancer sufferers interviewed for the study felt their doctor had not taken their concerns very seriously.
-- 44 per cent of the ovarian cancer sufferers interviewed had to wait more than six months for a correct diagnosis.
Ovarian cancer affects 6,800 women each year in Britain and only 30 per cent survive beyond five years – one of the lowest rates in Europe. However, the survival rate rises to 90 per cent among those who are diagnosed at an early stage.A new study shows that GPs often confuse the symptoms of ovarian cancer and irritable... more
-
-
For the second time this month, researchers report success using a novel type of anticancer pill to curb the growth of inherited tumors that often defy standard treatment. Called olaparib, the experimental pill is a member of a new class of drugs called PARP inhibitors that prevent unstable cancer cells from repairing themselves.
Two-thirds of 19 patients with cancer caused by mutations in the BRCA1 or BRCA2 genes responded to treatment with olaparib, and in more than half, tumors shrank or stopped growing, says researcher Johann de Bono, MD, PhD, of the Institute of Cancer Research in Sutton, U.K.
Defects in the BRCA1 and BRCA2 genes place women at sharply increased risk of developing aggressive cancers of the breast and ovaries at a young age. BRCA2 gene mutations also raise a man's risk of prostate cancer.
Of 19 patients in the study with BRCA-inherited cancers, 15 had ovarian cancer, three had breast cancer, and one had prostate cancer.
Olaparib did not help 41 other patients with tumors that were not associated with BRCA mutations, de Bono says.
PARP inhibitors "will very likely change the way we treat patients" whose tumors are caused by BRCA defects, says Daniel Silver, MD, PhD, of the Dana-Farber Cancer Institute in Boston. Silver, who was not involved with the work, co-authored an editorial about the study.
The study appears in the June 25 issue of The New England Journal of Medicine.For the second time this month, researchers report success using a novel type of... more
-
-
Seminar on genetic testing for breast and/or ovarian cancers with an opportunity to enroll in a clinical study.Seminar on genetic testing for breast and/or ovarian cancers with an opportunity to... more
-
-
Laboratory Corp of America is violating the law by selling an ovarian cancer screening test without regulatory approval, U.S. health officials said on Wednesday.
The OvaSure test does not fall in a category that can be sold without prior clearance from the agency, the Food and Drug Administration said.
"Because you do not have marketing clearance or approval from the FDA, marketing OvaSure is in violation of the law," the agency said in a letter dated Sept. 29.
The agency told the company to "take prompt action to correct these violations."
LabCorp spokesman Eric Lindblom said the company was "disappointed" by the letter.
"We are currently in discussions with the FDA over the next steps and of course we share the FDA's determination to assure patients are protected," he said.
The company started selling the blood test in June, saying it could detect early-stage ovarian cancer in high-risk women.
More than 21,000 women will be newly diagnosed with ovarian cancer in 2008 and more than 15,000 women will die from the disease, according to American Cancer Society estimates.
The five-year survival rate is 92 percent if the cancer is caught before it spreads, but only about 19 percent of cases are detected at that stage.
When the cancer is discovered in advanced stages, five-year survival drops to 30 percent.
The OvaSure test was developed by researchers at Yale University. A study of high-risk and average-risk women found it was 95 percent accurate in detecting ovarian cancer, LabCorp said when it announced the product's launch in June. False positives occurred for 0.6 percent of women.
Some doctors have complained the test does not have enough data behind it to support routine use.
The Society of Gynecologic Oncologists, in a statement issued in July, said "additional research is needed to validate the test's effectiveness before offering it to women outside of the context of a research study."
The FDA letter was posted on the FDA website here
LabCorp shares fell nearly 1.8 percent to close at $60.63 on the New York Stock Exchange.Laboratory Corp of America is violating the law by selling an ovarian cancer screening... more
-
-
Researchers at Yale have developed a very sensitive and specific blood test that is able to detect early stage ovarian cancer with 99% accuracy. Ovarian cancer is 3 times more common than breast cancer and is known as the "silent killer".Researchers at Yale have developed a very sensitive and specific blood test that is... more
-
-
Tori
-
added this
-
3 years ago
- |
